NeuroBo Pharmaceuticals, Inc.(NRBO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRBO NeuroBo Pharmaceuticals, Inc.

Pre-Market Trading 03-27 04:04:14 EDT

2.36

+0.00

0.00%

High2.36	Low2.36	Vol0.00
Open2.36	D1 Closing2.36	Amplitude0.00%
Mkt Cap20.33M	Tradable Cap5.18M	Total Shares8.62M
T/O31.15K	T/O Rate0.00%	Tradable Shares2.20M
P/B1.57	ROE-160.76%	EPS-4.29
52wk High6.75	52wk Low2.08	P/E-0.55
Dividend0.00	Div.Yield0.00	ROA-74.35%

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"NRBO","market":"US","secType":"STK","nameCN":"NeuroBo Pharmaceuticals, Inc.","latestPrice":2.36,"timestamp":1732741200000,"preClose":2.36,"halted":8,"volume":0,"delay":0,"floatShares":2196834,"shares":8616010,"eps":-4.294645,"marketStatus":"Pre-Market Trading","change":0,"latestTime":"03-27 04:04:14 EDT","open":2.36,"high":2.36,"low":2.36,"amount":31147.715098499997,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.294645,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743082200000},"marketStatusCode":1,"symbolChange":{"newSymbol":"MTVA","executeDate":"2024-11-29"},"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":2.36,"volumeRatio":0},"requestUrl":"/m/hq/s/NRBO/wiki","defaultTab":"wiki","newsList":[{"id":"2484273576","title":"BRIEF-Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To Metavia","url":"https://stock-news.laohu8.com/highlight/detail?id=2484273576","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484273576?lang=en_us&edition=full_marsco","pubTime":"2024-11-18 21:19","pubTimestamp":1731935979,"startTime":"0","endTime":"0","summary":"BRIEF-Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To MetaviaNov 18 (Reuters) - Neurobo Pharmaceuticals Inc NRBO.O:NEUROBO PHARMACEUTICALS INC:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MO02R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRBO"],"gpt_icon":0},{"id":"2484622815","title":"NeuroBo Pharmaceuticals Inc: Common Stock Will Begin Trading on Nasdaq Under \"Mtva,\" Which Is Expected to Be Operative as of November 29","url":"https://stock-news.laohu8.com/highlight/detail?id=2484622815","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484622815?lang=en_us&edition=full_marsco","pubTime":"2024-11-18 21:01","pubTimestamp":1731934913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MO02R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRBO","BK4139"],"gpt_icon":0},{"id":"2484162407","title":"NeuroBo Pharmaceuticals Inc: Strategic Realignment Ahead of Important Clinical Milestones With Name Change to Metavia","url":"https://stock-news.laohu8.com/highlight/detail?id=2484162407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484162407?lang=en_us&edition=full_marsco","pubTime":"2024-11-18 21:01","pubTimestamp":1731934913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MO02R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRBO"],"gpt_icon":0},{"id":"2484221346","title":"NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2484221346","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484221346?lang=en_us&edition=full_marsco","pubTime":"2024-11-18 21:01","pubTimestamp":1731934860,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to \"MetaVia Inc.,\" which will be effective on November 29, 2024 . In parallel, the Company's common stock will begin trading on the Nasdaq Stock Market under the new ticker symbol, \"MTVA,\" which is expected to be operative as of the Effective Date. As part of its corporate name change, the company will also launch a new website, metaviatx.com, and a new company logo, on the Effective Date.\"Our corporate name change to MetaVia, ahead of important clinical milestones, represents the final step in our transition to develop innovative therapies for the management of cardiometabolic diseases, since in-licensing our two next generation assets from our strategic partner, Dong-A ST Co., Ltd., targeting the obesity and m","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/eiaQP0kOEzEPnQd6voMuVQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/9430054a1694f5bedb5c47b111bd075c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/eiaQP0kOEzEPnQd6voMuVQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/9430054a1694f5bedb5c47b111bd075c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurobo-pharmaceuticals-announces-strategic-realignment-130100726.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurobo-pharmaceuticals-announces-strategic-realignment-130100726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRBO","BK4139","BK4202","OXM"],"gpt_icon":0},{"id":"2483376412","title":"Life Sciences Investor Forum: Presentations Now Available for Online Viewing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483376412","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483376412?lang=en_us&edition=full_marsco","pubTime":"2024-11-15 21:35","pubTimestamp":1731677700,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 15, 2024  -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held November 14th are now available for online viewing.The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section.Select companies are accepting 1x1 management meeting requests through November 19th.Virtual Investor Conferences  is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/life-sciences-investor-forum-presentations-133500021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DRMA","FET","MBCOF","CGTX","DRMAW","ZVSA","NRBO","BK4179"],"gpt_icon":0},{"id":"2483814007","title":"NeuroBo Pharmaceuticals to Participate in Investor Conferences in November","url":"https://stock-news.laohu8.com/highlight/detail?id=2483814007","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483814007?lang=en_us&edition=full_marsco","pubTime":"2024-11-13 21:01","pubTimestamp":1731502860,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November:. To schedule a meeting with management outside of these events, investors can contact Michael Miller at mmiller@rxir.com.About NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals, Inc.is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis . DA-1726 is a novel oxyntomodulin  analogue that functions as a glucagon-like peptide-1 receptor  and glucagon receptor  dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in su","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fdShppug0prWllvQvqPwYg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/34787696a5293c5eb009caa352963d4a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fdShppug0prWllvQvqPwYg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/34787696a5293c5eb009caa352963d4a"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurobo-pharmaceuticals-participate-investor-conferences-130100948.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurobo-pharmaceuticals-participate-investor-conferences-130100948.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRBO","BK4139","BK4202","OXM"],"gpt_icon":0},{"id":"2483856300","title":"NRBO:  Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483856300","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483856300?lang=en_us&edition=full_marsco","pubTime":"2024-11-13 20:00","pubTimestamp":1731499200,"startTime":"0","endTime":"0","summary":"NeuroBo Pharmaceuticals, Inc.  is developing DA-1241 as a treatment for metabolic dysfunction-associated steatohepatitis . DA-1241 is a novel chemical entity that selectively activates GPR119, stimulates the secretion of insulin and incretin hormones such as glucagon-like peptide-1 , reduces plasma glucose levels without causing hypoglycemia, and lowers plasma lipid levels of both triglycerides and cholesterol.MAD Part 2 Results from Phase 1 Trial of DA-1726 Expected in 1Q25. The multiple ascending dose  Part 2 of the trial is ongoing, with the first patient enrolled in June 2024. A total of 36 individuals are expected to be enrolled in Part 2 of the trial in a 6:3 ratio across four dosing cohorts. Each participant will receive four weekly administrations of DA-1726 or placebo. The last patient visit is expected in the fourth quarter of 2024 and topline results from Part 2 are expected in the first quarter of 2025.The company continues planning for Part 3 of the trial, which we anticip","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sx1iJ479PrW6SYfz5rrUXw--~B/aD00NTY7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/scr.zacks.com/f82628c29d5ea9c086b94a661e62e36c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sx1iJ479PrW6SYfz5rrUXw--~B/aD00NTY7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/scr.zacks.com/f82628c29d5ea9c086b94a661e62e36c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrbo-topline-results-phase-2a-120000295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4181","BK4139","NRBO","PK","ALT","LU1878469433.USD"],"gpt_icon":0},{"id":"2482170219","title":"Life Sciences Investor Forum Agenda Announced for November 14th","url":"https://stock-news.laohu8.com/highlight/detail?id=2482170219","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482170219?lang=en_us&edition=full_marsco","pubTime":"2024-11-12 21:35","pubTimestamp":1731418500,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 12, 2024  -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum to be held November 14th. This event is co-sponsored by Zacks SCR.Individual investors, institutional investors, advisors, and analysts are invited to attend.It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.“We’re pleased to feature a group of innovative companies at the upcomingLife Sciences Investor Forum,” said Jason Paltrowitz, Executive Vice President at OTC Markets Group. “Co-sponsored by Zacks Small Cap Research, this virtual conference will provide these companies with the opportunity to share their business strategies and engage more investors.”Virtual Investor Conferences Contact:John M. ViglottiSVP Corporate Services, Investor AccessOTC","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/life-sciences-investor-forum-agenda-133500963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FET","BK4588","DRMA","ZVSA","BK4585","BK4561","BK4179","CGTX","BK4590","BK4581","ET","NRBO","DRMAW","BK4144"],"gpt_icon":0},{"id":"2481932483","title":"NeuroBo Pharmaceuticals Inc  expected to post a loss of 89 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2481932483","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481932483?lang=en_us&edition=full_marsco","pubTime":"2024-11-08 23:49","pubTimestamp":1731080958,"startTime":"0","endTime":"0","summary":"NeuroBo Pharmaceuticals Inc  expected to post a loss of89cents a share - Earnings Preview NeuroBo Pharmaceuticals Inc NRBO.OQ NRBO.O is expected to show no change in quarterly revenue when it reports ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF24Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRBO"],"gpt_icon":0},{"id":"2481902906","title":"NeuroBo Pharmaceuticals Q3 2024 GAAP EPS $(0.55) Beats $(0.73) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481902906","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481902906?lang=en_us&edition=full_marsco","pubTime":"2024-11-07 21:23","pubTimestamp":1730985784,"startTime":"0","endTime":"0","summary":"NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.73) by 24.66 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41806103/neurobo-pharmaceuticals-q3-2024-gaap-eps-0-55-beats-0-73-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"NeuroBo Pharmaceuticals Q3 2024 GAAP EPS $(0.55) Beats $(0.73) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRBO"],"gpt_icon":0},{"id":"2481890482","title":"NeuroBo Pharmaceuticals: Cash Was Approximately $21.7 Million as of September 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481890482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481890482?lang=en_us&edition=full_marsco","pubTime":"2024-11-07 21:01","pubTimestamp":1730984463,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA3ZZZ0W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRBO","BK4139"],"gpt_icon":0},{"id":"2481490147","title":"NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481490147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481490147?lang=en_us&edition=full_marsco","pubTime":"2024-11-07 21:01","pubTimestamp":1730984463,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA3ZZZ0W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRBO"],"gpt_icon":0},{"id":"2480658612","title":"BRIEF-Neurobo Pharmaceuticals Completes Last Patient Last Visit In Its Phase 2A Clinical Trial Evaluating Da-1241 For The Treatment Of Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2480658612","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480658612?lang=en_us&edition=full_marsco","pubTime":"2024-11-04 22:17","pubTimestamp":1730729867,"startTime":"0","endTime":"0","summary":"Nov 4  - Neurobo Pharmaceuticals Inc   :   * NEUROBO PHARMACEUTICALS COMPLETES LAST PATIENT LAST VISIT IN ITS PHASE 2A CLINICAL TRIAL EVALUATING DA-1241 FOR THE TREATMENT OF MASH   * NEUROBO PHARMACEUTICALS INC - TOPLINE DATA READOUT EXPECTED IN DECEMBER 2024Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRBO","BK4139"],"gpt_icon":0},{"id":"2480300839","title":"NeuroBo Pharmaceuticals Inc - Topline Data Readout Expected in December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2480300839","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480300839?lang=en_us&edition=full_marsco","pubTime":"2024-11-04 21:01","pubTimestamp":1730725262,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nTUAB57NJQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRBO","BK4139"],"gpt_icon":0},{"id":"2480300837","title":"NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating Da-1241 for the Treatment of Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2480300837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480300837?lang=en_us&edition=full_marsco","pubTime":"2024-11-04 21:01","pubTimestamp":1730725262,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nTUAB57NJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRBO"],"gpt_icon":0},{"id":"2480300437","title":"NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2480300437","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480300437?lang=en_us&edition=full_marsco","pubTime":"2024-11-04 21:01","pubTimestamp":1730725260,"startTime":"0","endTime":"0","summary":"Topline Data Readout From Part 1 and Part 2 Expected in December 2024. CAMBRIDGE, Mass., Nov. 4, 2024 /PRNewswire/ --NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of the last patient last visit in its two-part, Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein-Coupled Receptor 119  agonist for the treatment of metabolic dysfunction-associated steatohepatitis .For both Part 1 and Part 2, the primary endpoint is the change from baseline in alanine transaminase  levels at Week 16. Secondary efficacy endpoints include the proportion of subjects with normalization of ALT, absolute change in total cholesterol, low and high-density lipoprotein cholesterol, triglycerides, and free fatty acids from baseline, among others. Safety will be evaluated by monitoring adverse events  and serious adverse events  leading to discontinuation and laboratory abnorma","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Bg.6D7Ld1M.O0UAdMw_zQA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/8f5d9238bed9182f7713a0d63e865265","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Bg.6D7Ld1M.O0UAdMw_zQA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/8f5d9238bed9182f7713a0d63e865265"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurobo-pharmaceuticals-completes-last-patient-130100079.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurobo-pharmaceuticals-completes-last-patient-130100079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4202","OXM","LU1878469433.USD","BK4139","ALT","NRBO"],"gpt_icon":0},{"id":"2472307012","title":"NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…","url":"https://stock-news.laohu8.com/highlight/detail?id=2472307012","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472307012?lang=en_us&edition=full_marsco","pubTime":"2024-10-01 21:30","pubTimestamp":1727789400,"startTime":"0","endTime":"0","summary":"On September 30, 2024, NeuroBo Pharmaceuticals, Inc.  announced positive topline results for the single ascending dose  Part 1 of the ongoing Phase 1 clinical trial of DA-1726 for the treatment of obesity. A total of 45 obese but otherwise healthy individuals were randomized in a double blind, 6:3 ratio to receive DA-1726 or placebo. The results showed that DA-1726 was safe, well tolerated, and had linear pharmacokinetics . In regards to safety, only five subjects in the DA-1726 group reported adverse events  compared to three subjects in the placebo group. Due to the strong safety profile, at least one additional dosing cohort is being added to evaluate the maximum tolerated dose.The multiple ascending dose  Part 2 of the trial is ongoing, with the first patient enrolled in June 2024. A total of 36 individuals are expected to be enrolled in Part 2 of the trial in a 6:3 ratio across four dosing cohorts. Each participant will receive four weekly administrations of DA-1726 or placebo. To","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/RRSNJfSPx2PAmdImCIrE3g--~B/aD0xMDI4O3c9MTc0MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/scr.zacks.com/023816fda1d0fb3f28872c65452b27eb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/RRSNJfSPx2PAmdImCIrE3g--~B/aD0xMDI4O3c9MTc0MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/scr.zacks.com/023816fda1d0fb3f28872c65452b27eb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrbo-positive-sad-part-1-133000495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4181","PK","NRBO","BK4139"],"gpt_icon":1},{"id":"2472324739","title":"NeuroBo Pharmaceuticals to Participate in Investor Conferences in October","url":"https://stock-news.laohu8.com/highlight/detail?id=2472324739","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472324739?lang=en_us&edition=full_marsco","pubTime":"2024-10-01 20:01","pubTimestamp":1727784060,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Oct. 1, 2024 /PRNewswire/ --NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that management will participate in the following investor conferences in October:. October 15-17: 2024 Maxim Healthcare Virtual Summit. Mr. Kim and Marshall H. Woodworth, Chief Financial Officer, will participate in a virtual fireside chat hosted by Jason McCarthy, Ph.D., senior managing director, head of biotechnology research at Maxim Group, on Tuesday, October 15, at 2:30 pm ET.To schedule a meeting with management outside of these conferences, investors can contact Michael Miller at mmiller@rxir.com.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KnxWUS7o.znVHJT4WUH3zQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/77b339c13137d33fdd13b94360635e4a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KnxWUS7o.znVHJT4WUH3zQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/77b339c13137d33fdd13b94360635e4a"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurobo-pharmaceuticals-participate-investor-conferences-120100402.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurobo-pharmaceuticals-participate-investor-conferences-120100402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4202","BK4139","NRBO","OXM"],"gpt_icon":0},{"id":"2471138748","title":"We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2471138748","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471138748?lang=en_us&edition=full_marsco","pubTime":"2024-09-30 23:07","pubTimestamp":1727708830,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?So should NeuroBo Pharmaceuticals  shareholders be worried about its cash burn?In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn.Since it has a market capitalisation of US$28m, NeuroBo Pharmaceuticals' US$20m in cash burn equates to about 71% of its market value. That's very high expenditure relative to the company's size, suggesting it is an extremely high risk stock.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-little-worried-neurobo-pharmaceuticals-150710035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","IE00BGHQF748.EUR","LU2095319765.USD","QLD","NRBO","BK4112","QID","NDAQ","TQQQ","PSQ","LU2210149790.SGD","MNQmain","NQmain","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4585","BK4588","IE00BKPKM429.USD","SQQQ","BK4139"],"gpt_icon":1},{"id":"2471024828","title":"BRIEF-Neurobo Pharmaceuticals Announces Positive Top-Line Data From The SAD Part 1 Of Phase 1 Clinical Trial Evaluating DA-1726","url":"https://stock-news.laohu8.com/highlight/detail?id=2471024828","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471024828?lang=en_us&edition=full_marsco","pubTime":"2024-09-30 20:39","pubTimestamp":1727699992,"startTime":"0","endTime":"0","summary":"Sept 30  - Neurobo Pharmaceuticals Inc :   * NEUROBO PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE DATA FROM THE SAD PART 1 OF ITS PHASE 1 CLINICAL TRIAL EVALUATING DA-1726 FOR THE TREATMENT OF OBESITY   * NEUROBO PHARMACEUTICALS INC - DATA SHOWS FAVORABLE SAFETY, TOLERABILITY, AND DOSE-LINEAR PK   * NEUROBO PHARMACEUTICALS INC - TOP-LINE DATA FROM MAD PART 2 EXPECTED Q1 2025Source text for Eikon:   Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRBO","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurobopharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":-0.2892},{"period":"1year","weight":-0.4512},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0479},{"period":"3month","weight":-0.0545},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.096},{"period":"ytd","weight":-0.0298}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.101843},{"month":2,"riseRate":0.375,"avgChangeRate":0.080599},{"month":3,"riseRate":0.5,"avgChangeRate":-0.020088},{"month":4,"riseRate":0.375,"avgChangeRate":-0.098642},{"month":5,"riseRate":0.25,"avgChangeRate":-0.104755},{"month":6,"riseRate":0.625,"avgChangeRate":0.103229},{"month":7,"riseRate":0.25,"avgChangeRate":-0.022415},{"month":8,"riseRate":0.125,"avgChangeRate":-0.219737},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019058},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.212992},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.109043},{"month":12,"riseRate":0.125,"avgChangeRate":-0.172588}],"exchange":"NASDAQ","name":"NeuroBo Pharmaceuticals, Inc.","nameEN":"NeuroBo Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NeuroBo Pharmaceuticals, Inc.(NRBO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NeuroBo Pharmaceuticals, Inc.(NRBO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NeuroBo Pharmaceuticals, Inc.,NRBO,NeuroBo Pharmaceuticals, Inc.股票,NeuroBo Pharmaceuticals, Inc.股票老虎,NeuroBo Pharmaceuticals, Inc.股票老虎国际,NeuroBo Pharmaceuticals, Inc.行情,NeuroBo Pharmaceuticals, Inc.股票行情,NeuroBo Pharmaceuticals, Inc.股价,NeuroBo Pharmaceuticals, Inc.股市,NeuroBo Pharmaceuticals, Inc.股票价格,NeuroBo Pharmaceuticals, Inc.股票交易,NeuroBo Pharmaceuticals, Inc.股票购买,NeuroBo Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NeuroBo Pharmaceuticals, Inc.(NRBO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NeuroBo Pharmaceuticals, Inc.(NRBO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction